SECURITIES AND EXCHANGE COMMISSION
----------------------------------
WASHINGTON, D.C. 20549
___________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 28, 2000
Cistron Biotechnology, Inc.
---------------------------
(Exact name of registrant as specified in charter)
Delaware 0-15271 22-2487972
(State or other jurisdiction (Commission File (IRS Employer
of incorporation) Number) Identification No.)
10 Bloomfield Avenue, Pine Brook, New Jersey 07058
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (973) 575-1700
Not Applicable
(Former name or former address, if changed since last report)
<PAGE> 2
Item 4. Changes in Registrant's Certifying Accountant.
----------------------------------------------
On January 28, 2000, Cistron Biotechnology, Inc. (the
"Company") dismissed the firm of Deloitte & Touche, LLP
("Deloitte") as certifying accountants. In their place, the
Company has engaged the firm of Wiss and Company to act as
certifying accountants for the fiscal year ended June 30, 2000.
The Company's Board of Directors unanimously approved the
dismissal of Deloitte & Touche, LLP and the engagement of Wiss
and Company.
For the prior two fiscal years, the opinions of Deloitte
have been unqualified with respect to uncertainty, audit scope and
accounting principle. Further, during those two prior fiscal years
and the interim portion of the current fiscal year, there have been
no disagreements with Deloitte on any matter of accounting principle
or practice, financial statement disclosure, audit scope or audit
procedure which disagreements, if not resolved to the satisfaction
of Deloitte, would have caused it to make reference to the subject
matter of the disagreements in connection with its report.
Deloitte has been provided with a copy of the foregoing statements
in respect to Item 304(a) and its letter of response has been attached
hereto as an exhibit.
Item 7. Financial Statements, Pro Forma Financial Information
and Exhibits.
-----------------------------------------------------
(c) Exhibits. The following exhibit is filed herewith:
No. DESCRIPTION
--- -----------
16.1 Letter from Deloitte & Touche dated February 3, 2000.
<PAGE> 3
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
Cistron Biotechnology, Inc.
(Registrant)
By: /s/ISIDORE S. EDELMAN
-------------------------
Isidore S. Edelman
Chairman & CEO
Dated: February 3, 2000
<PAGE> 4
EXHIBIT INDEX
-------------
Exhibit Number Description
- - -------------- -----------
16.1 Letter from Deloitte & Touche dated February 3, 2000.
<PAGE> 5
Deloitte & Touche LLP
Two Hilton Court
PO Box 319
Parsippany, New Jersey 07054-0319
Telephone: (973) 683-7000
Facsimile: (973) 683-7459
February 3, 2000
Isidore S. Edelman, M.D.
Chairman & Chief Executive Officer
Cistron Biotechnology Inc.
P.O. Box 2004
10 Bloomfield avenue
Pine Brook, NJ 07058
Dear Dr. Edelman:
This is to confirm that the client-auditor relationship between
Cistron Biotechnology, Inc. (Comission File No. 0-15271) and
Deloitte & Touche LLP has ceased.
Yours truly,
/s/Deloitte & Touche LLP
- - ------------------------
Deloitte & Touche LLP
Cc: Office of the Chief Accountant
SECOS Letter File
Securities and Exchange Commission
Mail Stop 9-5
450 5th Street, N.W.
Washington, D.C. 20549
